OSTX (OS Therapies) Current Accrued Expense: $0.02 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTX OS Therapies Inc OSTX
8 GF Score
Price $1.68
! 4 Warning Signs
View Full Analysis

What is OS Therapies Current Accrued Expense?

OS Therapies OSTX -7.69% 8 Current Accrued Expense is $0.02 Mil as of Jun. 2026. GuruFocus rates OSTX with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

OS Therapies's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.02 Mil.

OS Therapies's quarterly Current Accrued Expense declined from Dec. 2025 ($1.45 Mil) to Mar. 2026 ($0.00 Mil) but then increased from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.02 Mil).

OS Therapies's annual Current Accrued Expense declined from Dec. 2023 ($2.34 Mil) to Dec. 2024 ($0.62 Mil) but then increased from Dec. 2024 ($0.62 Mil) to Dec. 2025 ($1.45 Mil).

OS Therapies Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for OS Therapies's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OS Therapies Current Accrued Expense Chart

OS Therapies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.93 1.67 2.34 0.62 1.45

OS Therapies Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.40 1.45 0.00 0.02
OSTX
8GF Score
OS Therapies Inc OSTX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OS Therapies Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.02 Mil mean?
OS Therapies (OSTX) has a Current Accrued Expense of $0.02 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on OS Therapies and its competitors.
Is OS Therapies' Current Accrued Expense too high?
OS Therapies' current Current Accrued Expense is $0.02 Mil. Overall, OS Therapies has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OS Therapies' Current Accrued Expense compare to APLM and NRXS?
OS Therapies' Current Accrued Expense of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on OS Therapies and its competitors. OS Therapies's current Current Accrued Expense is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OS Therapies stock overvalued right now?
OS Therapies (OSTX) has a current Current Accrued Expense of $0.02 Mil. The current Current Accrued Expense is $0.02 Mil. OS Therapies' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For OS Therapies (OSTX), the current Current Accrued Expense is $0.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OS Therapies Business Description

Address 115 Pullman Crossing Road, Suite 103, Grasonville, MD, USA, 21638
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
8GF Score

Get the complete analysis for OSTX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.68
Price